Abstract
Apparent differences in the effectiveness of adjuvant therapies according to age, has led to controversy concerning the optimum treatment for women with breast cancer above and below 50 years of age. The data upon which this controversy is based and the possible reasons why chemotherapy appears more active in young women, whilst endocrine therapy appears more active in older women, is examined.
| Original language | English |
|---|---|
| Pages (from-to) | 231-7 |
| Number of pages | 7 |
| Journal | Hormone Research |
| Volume | 32 Suppl 1 |
| Publication status | Published - 1989 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adult
- Age Factors
- Antineoplastic Agents
- Breast Neoplasms
- Drug Evaluation
- Female
- Humans
- Middle Aged
- Tamoxifen
- Journal Article
Fingerprint
Dive into the research topics of 'The relationship between age and the effect of adjuvant therapies in women with primary breast cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver